We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Drug Evaluation

Selegiline transdermal system in the treatment of depressive disorders

    Thomas C Baghai

    † Author for correspondence

    Ludwig–Maximilian University of Munich, Department of Psychiatry & Psychotherapy, Nussbaumstrasse 7, D-80336 Munich, Germany.

    Search for more papers by this author

    Email the corresponding author at baghai@med.uni-muenchen.de

    ,
    Daniela Eser

    Ludwig–Maximilian University of Munich, Department of Psychiatry & Psychotherapy, Nussbaumstrasse 7, D-80336 Munich, Germany.

    Search for more papers by this author

    Email the corresponding author at daniela.eser@med.uni-muenchen.de

    ,
    Cornelius Schule

    Ludwig–Maximilian University of Munich, Department of Psychiatry & Psychotherapy, Nussbaumstrasse 7, D-80336 Munich, Germany.

    Search for more papers by this author

    Email the corresponding author at cornelius.schuele@med.uni-muenchen.de

    ,
    Christoph Born

    Ludwig–Maximilian University of Munich, Department of Psychiatry & Psychotherapy, Nussbaumstrasse 7, D-80336 Munich, Germany.

    Search for more papers by this author

    Email the corresponding author at christoph.born@med.uni-muenchen.de

    &
    Rainer Rupprecht

    Ludwig–Maximilian University of Munich, Department of Psychiatry & Psychotherapy, Nussbaumstrasse 7, D-80336 Munich, Germany.

    Search for more papers by this author

    Email the corresponding author at rainer.rupprecht@med.uni-muenchen.de

    Published Online:25 Oct 2007https://doi.org/10.2217/14796708.2.6.601

    Abstract

    Selegiline is a selective irreversible inhibitor of monoamine oxidase (MAO)-B during low-dose oral treatment. Additional MAO-A inhibition occurs in higher dose ranges. Selegiline transdermal system (STS) shows a more potent MAO inhibition in comparison with orally administered selegiline, and at minimum doses of 20 mg/20 cm2 patch delivering 6 mg/24 h, no dietary restrictions, including low-tyramine food, are necessary. While oral selegiline has been used for years in the treatment of Parkinson’s disease, the US FDA recently approved the STS for use in treating major depression. Data from three randomized controlled trials showed a significantly better efficacy of STS in the treatment of unipolar major depression in comparison with placebo during 6–8 weeks of treatment. In addition, one long-term randomized controlled trial demonstrated the efficacy of the STS in relapse prevention of unipolar depression over 1 year. A total number of 515 depressed patients received STS during these studies. The tolerability profile of STS without dietary restrictions was excellent. The only side effects that were more frequent than with placebo were application-site reactions. No change in vital parameters and no hypertensive crisis have been recorded. Comparative studies including treatment with established antidepressants and the investigation of bipolar depressed patients and of specific patient subgroups (e.g., anergic and atypical depression) have to follow. The combination of the well-known effectiveness of irreversible MAO inhibitors with a good tolerability profile and a new pharmaceutical form, possibly enhancing compliance, represents a promising further expansion of the pharmacotherapeutic repertoire in the treatment of depression.

    Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

    Bibliography

    • 1  Sartorius N: The economic and social burden of depression. J. Clin. Psychiatry62(Suppl. 15),S8–S11 (2001).• Review indicating the outstanding importance of adequate treatment of depressive disorders.
      MedlineGoogle Scholar
    • 2  Paykel ES, Brugha T, Fryers T: Size and burden of depressive disorders in Europe. Eur. Neuropsychopharmacol.15(4),411–423 (2005).
      Medline CASGoogle Scholar
    • 3  Ebmeier KP, Donaghey C, Steele JD: Recent developments and current controversies in depression. Lancet367(9505),153–167 (2006).
      MedlineGoogle Scholar
    • 4  Andrade L, Caraveo-Anduaga JJ, Berglund P et al.: The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int. J. Methods Psychiatr. Res.12(1),3–21 (2003).
      MedlineGoogle Scholar
    • 5  Demyttenaere K, Bruffaerts R, Posada-Villa J et al.: Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA291(21),2581–2590 (2004).
      MedlineGoogle Scholar
    • 6  Kessler RC: Epidemiology of women and depression. J. Affect. Disord.74(1),5–13 (2003).
      MedlineGoogle Scholar
    • 7  Nierenberg AA, Trivedi MH, Fava M et al.: Family history of mood disorder and characteristics of major depressive disorder: a STAR(*)D (sequenced treatment alternatives to relieve depression) study. J. Psychiatr. Res.41(3–4),214–221 (2007).
      MedlineGoogle Scholar
    • 8  Kessler RC, Berglund P, Demler O et al.: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA289(23),3095–3105 (2003).
      MedlineGoogle Scholar
    • 9  ECT review group: Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet361(9360),799–808 (2003).
      MedlineGoogle Scholar
    • 10  Charney DS, Grothe DR, Smith SL et al.: Overview of psychiatric disorders and the role of newer antidepressants. J. Clin. Psychiatry63,3–9 (2002).
      MedlineGoogle Scholar
    • 11  Rush AJ, Trivedi MH, Wisniewski SR et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry163(11),1905–1917 (2006).
      MedlineGoogle Scholar
    • 12  Thase ME, Greenhouse JB, Frank E et al.: Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch. Gen. Psychiatry54(11),1009–1015 (1997).
      Medline CASGoogle Scholar
    • 13  Kent JM: SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet355(9207),911–918 (2000).
      Medline CASGoogle Scholar
    • 14  Stahl SM: Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J. Clin. Psychiatry59,23–29 (1998).• Review providing information for optimal and individualized antidepressant pharmacotherapy.
      Medline CASGoogle Scholar
    • 15  Audinot V, Mailliet F, Lahaye-Brasseur C et al.: New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch. Pharmacol.367(6),553–561 (2003).
      Medline CASGoogle Scholar
    • 16  Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression. Neuropsychopharmacology12(3),185–219 (1995).
      Medline CASGoogle Scholar
    • 17  Lotufo-Neto F, Trivedi M, Thase ME: Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology20(3),226–247 (1999).
      Medline CASGoogle Scholar
    • 18  Fernandez HH, Chen JJ: Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin. Neuropharmacol.30(3),150–168 (2007).
      Medline CASGoogle Scholar
    • 19  Mahmood I: Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson’s disease? Ther. Drug Monit.20(6),717–721 (1998).
      Medline CASGoogle Scholar
    • 20  Robinson DS: Monoamine oxidase inhibitors: a new generation. Psychopharmacol. Bull.36(3),124–138 (2002).
      MedlineGoogle Scholar
    • 21  Mahmood I: Selegiline transdermal system Somerset. Curr. Opin. Investig. Drugs3(8),1230–1233 (2002).
      Medline CASGoogle Scholar
    • 22  Mahmood I: Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin. Pharmacokinet.33(2),91–102 (1997).
      Medline CASGoogle Scholar
    • 23  Sunderland T, Mueller EA, Cohen RM et al.: Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl.)86(4),432–437 (1985).
      Medline CASGoogle Scholar
    • 24  Mann JJ, Aarons SF, Wilner PJ et al.: A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch. Gen. Psychiatry46(1),45–50 (1989).
      Medline CASGoogle Scholar
    • 25  Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin. Pharmacokinet.41(4),261–309 (2002).
      Medline CASGoogle Scholar
    • 26  Mawhinney M, Cole D, Azzaro AJ: Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J. Pharm. Pharmacol.55(1),27–34 (2003).
      Medline CASGoogle Scholar
    • 27  Shimazu S, Minami A, Kusumoto H et al.: Antidepressant-like effects of selegiline in the forced swim test. Eur. Neuropsychopharmacol.15(5),563–571 (2005).
      Medline CASGoogle Scholar
    • 28  Gordon MN, Muller CD, Sherman KA et al.: Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol. Biochem. Behav.63(3),501–506 (1999).
      Medline CASGoogle Scholar
    • 29  Magyar K, Palfi M, Tabi T et al.: Pharmacological aspects of (-)-deprenyl. Curr. Med. Chem.11(15),2017–2031 (2004).
      Medline CASGoogle Scholar
    • 30  Frampton JE, Plosker GL: Selegiline transdermal system: in the treatment of major depressive disorder. Drugs67(2),257–265 (2007).
      Medline CASGoogle Scholar
    • 31  Ziemniak J, Kemper EM, Goodhead M et al.: Pharmacokinetics of selegiline administered via transdermal patch, single oral dose or intravenous infusion. Presented at: 41st Annual Meeting New Clinical Drug Evaluation Unit (NCDEU). Phoenix, AZ, USA, 29 May (2001).
      Google Scholar
    • 32  Pae CU, Lim HK, Han C et al.: Selegiline transdermal system: current awareness and promise. Prog. Neuropsychopharmacol. Biol. Psychiatry31(6),1153–1163 (2007).
      Medline CASGoogle Scholar
    • 33  Rohatagi S, Barrett JS, DeWitt KE et al.: Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm. Drug Dispos.18(7),567–584 (1997).
      Medline CASGoogle Scholar
    • 34  Clarke A, Brewer F, Johnson ES et al.: A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural Transm.110(11),1241–1255 (2003).
      Medline CASGoogle Scholar
    • 35  Bodkin JA, Amsterdam JD: Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am. J. Psychiatry159(11),1869–1875 (2002).•• First randomized placebo-controlled trial demonstrating efficacy and tolerability of the selegiline transdermal system (STS) in major depressive patients.
      MedlineGoogle Scholar
    • 36  Amsterdam JD: A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J. Clin. Psychiatry64(2),208–214 (2003).•• Second randomized placebo-controlled trial demonstrating efficacy and tolerability of the STS in major depressive patients. First trial without dietary restrictions.
      Medline CASGoogle Scholar
    • 37  Feiger AD, Rickels K, Rynn MA et al.: Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J. Clin. Psychiatry67(9),1354–1361 (2006).•• Third randomized placebo-controlled trial demonstrating efficacy and tolerability of the STS in major depressive patients. First trial without dietary restrictions. First dose-titration study.
      Medline CASGoogle Scholar
    • 38  Amsterdam JD, Bodkin JA: Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J. Clin. Psychopharmacol.26(6),579–586 (2006).•• First randomized placebo-controlled long-term trial showing efficacy and tolerability of the selegiline transdermal system in the relapse prevention of major depression.
      Medline CASGoogle Scholar
    • 39  Himmelhoch JM, Thase ME, Mallinger AG et al.: Tranylcypromine versus imipramine in anergic bipolar depression. Am. J. Psychiatry148(7),910–916 (1991).
      Medline CASGoogle Scholar
    • 40  Thase ME, Mallinger AG, McKnight D et al.: Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am. J. Psychiatry149(2),195–198 (1992).
      Medline CASGoogle Scholar
    • 41  Morgan PT: Treatment-resistant depression: response to low-dose transdermal but not oral selegiline. J. Clin. Psychopharmacol.27(3),313–314 (2007).
      MedlineGoogle Scholar
    • 42  Amsterdam JD, Shults J: MAOI efficacy and safety in advanced stage treatment-resistant depression-A retrospective study. J. Affect. Disord.89(1–3),183–188 (2005).
      Medline CASGoogle Scholar
    • 43  Brown CS, Bryant SG: Monoamine oxidase inhibitors: safety and efficacy issues. Drug Intell. Clin. Pharm.22(3),232–235 (1988).
      Medline CASGoogle Scholar
    • 44  Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging13(5),341–355 (1998).
      Medline CASGoogle Scholar
    • 45  Robinson DS, Amsterdam JD: The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J. Affect. Disord. (2007) (Epub ahead of print).
      MedlineGoogle Scholar
    • 46  Azzaro AJ, Vandenberg CM, Ziemniak J, Kemper EM, Blob LF, Campbell BJ: Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. J. Clin. Pharmacol.47,978–990 (2007).
      Medline CASGoogle Scholar
    • 47  Barrett JS, Hochadel TJ, Morales RJ et al.: Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. J. Clin. Pharmacol.37(3),238–247 (1997).
      Medline CASGoogle Scholar
    • 48  Blob LF, Sharoky M, Campbell BJ et al.: Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. CNS Spectr.12(1),25–34 (2007).
      MedlineGoogle Scholar
    • 49  Azzaro AJ, Vandenberg CM, Blob LF et al.: Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J. Clin. Pharmacol.46(8),933–944 (2006).
      Medline CASGoogle Scholar
    • 50  Azzaro AJ, Ziemniak J, Kemper E et al.: Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J. Clin. Pharmacol.47(2),146–158 (2007).• Interaction study investigating the tolerability of STS with typical psychotropic concomitant medication.
      Medline CASGoogle Scholar
    • 51  Goodnick PJ: Seligiline transdermal system in depression. Expert Opin. Pharmacother.8(1),59–64 (2007).
      Medline CASGoogle Scholar
    • 52  Briggs NC, Jefferson JW, Koenecke FH: Tranylcypromine addiction: a case report and review. J. Clin. Psychiatry51(10),426–429 (1990).
      Medline CASGoogle Scholar
    • 53  Westermeyer J: Addiction to tranylcypromine (Parnate®): a case report. Am. J. Drug Alcohol Abuse15(3),345–350 (1989).
      Medline CASGoogle Scholar
    • 54  Ben-Arie O, George GC: A case of tranylcypromine (‘Parnate’) addiction. Br. J. Psychiatry135,273–274 (1979).
      Medline CASGoogle Scholar
    • 55  Nickel B, Schulze G, Szelenyi I: Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats. Neuropharmacology29(11),983–992 (1990).
      Medline CASGoogle Scholar
    • 56  McGrath PJ, Stewart JW, Fava M et al.: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am. J. Psychiatry163(9),1531–1541 (2006).
      MedlineGoogle Scholar
    • 57  Lieberman A: Depression in Parkinson’s disease: a review. Acta Neurol. Scand.113(1),1–8 (2006).
      Medline CASGoogle Scholar
    • 58  Sairanen M, O’Leary OF, Knuuttila JE et al.: Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience144(1),368–374 (2007).
      Medline CASGoogle Scholar
    • 59  Ruey-Meei W, Dennis LM, Chuang CC: Selegiline (l-deprenyl) as a unique neuroprotective agent for chronic neurodegenerative disorders – a lesson from MAO inhibition. In: Current Medicinal Chemistry – Central Nervous System Agents. Bentham Science Publishers, IL, USA 255–267 (2004).
      Google Scholar
    • 60  Sacktor N, Schifitto G, McDermott MP et al.: Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology54(1),233–235 (2000).
      Medline CASGoogle Scholar
    • 61  Rubinstein S, Malone MA, Roberts W et al.: Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol.16(4),404–415 (2006).
      MedlineGoogle Scholar
    • 62  Houtsmuller EJ, Notes LD, Newton T et al.: Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl.)172(1),31–40 (2004).
      Medline CASGoogle Scholar
    • 63  Elkashef A, Fudala PJ, Gorgon L et al.: Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend.85(3),191–197 (2006).
      Medline CASGoogle Scholar
    • 64  Houtsmuller EJ, Thornton JA, Stitzer ML: Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl.)163(2),213–220 (2002).
      Medline CASGoogle Scholar
    • 65  Biberman R, Neumann R, Katzir I et al.: A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction98(10),1403–1407 (2003).
      Medline CASGoogle Scholar
    • 101  WHO (2002). The Global Burden of Disease Project (Accessed 30 January 2007). www.who.int
      Google Scholar
    • 102  EMSAM (selegiline transdermal system); prescribing information. Bristol-Myers Squibb Company (Accessed 7 July 2007). www.bms.com
      Google Scholar
    • 103  US FDA Safety Information and Adverse Event Reporting Program 2007 (Accessed 12 July 2007). www.fda.gov/medwatch/index.html• Online access to reports about adverse events of pharmaceutical compounds.
      Google Scholar
    • 104  US FDA approves emsam (selegiline) as first drug patch for depression: 28 February 2006 (Accessed 10 July 2007). www.fda.gov/bbs/topics/NEWS/2006/NEW01326.html
      Google Scholar